MedPath

DAPSONE

These highlights do not include all the information needed to use dapsone gel, 5% safely and effectively. See full prescribing information for dapsone gel, 5%. Dapsone gel, 5%, for topical use Initial U.S. Approval: 1955

Approved
Approval ID

8dbe1a41-6d9d-414f-aa9c-09bd95857e2a

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 30, 2018

Manufacturers
FDA

Pacific Pharma, Inc.

DUNS: 877645267

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

dapsone

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code60758-670
Application NumberNDA021794
Product Classification
M
Marketing Category
C73605
G
Generic Name
dapsone
Product Specifications
Route of AdministrationTOPICAL
Effective DateApril 24, 2023
FDA Product Classification

INGREDIENTS (6)

CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED)Inactive
Code: 4Q93RCW27E
Classification: IACT
dapsoneActive
Quantity: 50 mg in 1 g
Code: 8W5C518302
Classification: ACTIB
DIETHYLENE GLYCOL MONOETHYL ETHERInactive
Code: A1A1I8X02B
Classification: IACT
METHYLPARABENInactive
Code: A2I8C7HI9T
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DAPSONE - FDA Drug Approval Details